University of Iowa
Iowa City, Iowa, 52240, United States
NCT Number: NCT05600725
This project utilizes a novel cardiac pacing approach hypothesized to initiate beneficial cardiac conditioning and remodeling over a period of time.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Iowa City, Iowa, 52240, United States
The project studies subjects with non-ischemic cardiomyopathy who have a pacing device already implanted. Subjects randomized to the pacing intervention versus a sham intervention will be compared for various symptomatic, functional and other outcomes. Each subject will undergo baseline quality of life/symptom questionnaires and clinical testing for cardiac functional/structural effects and exercise tolerance, then the intervention vs. sham (subjects blinded to their category), followed by repeat questionnaires and clinical testing. Medical record review will be undertaken to establish demographic variables, baseline and follow up testing results.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
Time frame: 4 weeks after start of the protocol
Minnesota Living with Heart Failure Score (range 0-105, higher scores indicate worse quality of life)
Time frame: every 5 minutes during intervention/sham in weeks 1-4 of the protocol
systolic blood pressure (mmHg) as a continuous variable
Time frame: every 5 minutes during intervention/sham in weeks 1-4 of the protocol
systolic blood pressure (mmHg) as a continuous variable
Time frame: every 5 minutes during intervention/sham in weeks 1-4 of the protocol
oxygen saturation by pulse oximeter (%) as a continuous variable
Time frame: every 5 minutes during intervention/sham in weeks 1-4 of the protocol
cardiac output (liters/minute) as measured by thoracic impedance and reported as a continuous variable
Time frame: 4 weeks and 4 months after start of the protocol
Major adverse cardiac events: composite of total death, MI, stroke, hospitalization due to heart failure, revascularization
Time frame: at the time of enrollment, and at 4 weeks after start of the protocol
distance ambulated in 6 minutes (meters)
Denise Hodgson-Zingman
Other
Novel Pacing Modality to Initiate Favorable Cardiac Remodeling in Heart Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04737265
Breast Cancer, Breast Diseases
Duarte, California, United States
View Trial DetailsNCT06893731
Cardiomyopathies, Cardiovascular Diseases
Beijing, China
View Trial DetailsNCT03749551
Cardiomegaly, Cardiomyopathies
Frankfurt am Main, Hesse, Germany
View Trial DetailsNCT04166331
Cardiomyopathies, Cardiovascular Diseases
Orléans, Orleans, France
View Trial Details